BioMarker Strategies
ASCO Data Bolster Talzenna, Xtandi Benefit in HRR-Mutant mCRPC as Pfizer Pursues Allcomers Approval
Premium
Biomarker-selected patients benefited from the added PARP inhibitor, but oncologists still don't know what to think about the benefit in patients without HRR mutations.
Culmination Bio, Cofactor Genomics Team up on Study to Advance Immunotherapy Response Test
Culmination will give Cofactor access to over 4.5 million biological samples to advance the firm's assay to predict immunotherapy response in 11 cancer types.
LXRepair, Gustave Roussy Ink Research Partnership in Personalized Radiotherapy
The French biotech and cancer center have launched a joint lab to advance LXRepair's DNA-based functional assays to predict patients' responses to radiation.
Early ESMO Data Show Interferon Signature's Ability to Guide Neoadjuvant Melanoma Immunotherapy
In the Phase I DOMINI trial, patients received combinations of BMS' Opdivo, Yervoy, and 4SC's domatinostat based on their tumors' interferon gamma gene expression.
BioMarker Strategies Wins NCI Grant to Develop Head and Neck Cancer CDx
The company is developing a companion diagnostic to identify head and neck cancer patients most likely to benefit from Erbitux.